FRLN - Freeline begins dosing patients in confirmatory trial to treat hemophilia B

Freeline Therapeutics (NASDAQ:FRLN) said on Tuesday it had begun dosing the second cohort in its Phase 1/2 dose confirmation trial of FLT180a in people with hemophilia B. The company said patients in cohort two will receive the same low dose (7.7e11 vg/kg) of FLT180a and optimized prophylactic immune management regimen that were used in the first cohort. Dosing for the first cohort was completed in April and initial data are expected to be presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress between July 9-13. FRLN expects Phase 3 trial to begin in 2023 as planned. Freeline plans to report updated data from the trial in the second half of 2022 and the first half of 2023.

For further details see:

Freeline begins dosing patients in confirmatory trial to treat hemophilia B